Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised “tens of millions” of US dollars in another financing round. The round was led by Yuanbio Venture Capital, with participation from OrbiMed, Cenova Ventures, Lilly Asia Ventures, Gaorong Capital, Huihe Capital, and GC&H Investments. The proceeds will be used for continuous research and development (R&D) investment, clinical trials, product regulatory filings, commercialization layout, team building at home and abroad, and operational and manufacturing capability expansion.
Company Profile and Product Series
Founded in 2013, Pulnovo Medical boasts its pulmonary artery denervation (PADN) product series. Among them, its multipolar synchronous pulmonary artery radiofrequency ablation catheter was designated Breakthrough Device Program status in the US in 2021. The product completed all patient follow-up for the regulatory PADN-NMPA study, highlighting its potential to address significant unmet needs in the treatment of pulmonary hypertension.
Future Development Plans
The funding will support Pulnovo Medical’s ongoing efforts to advance its PADN product series, enhance clinical research, and expand its global market presence. This strategic investment underscores the company’s commitment to innovation and improving patient outcomes in the field of pulmonary hypertension.-Fineline Info & Tech
